Neurocrine Biosciences | NBIX - Selling And Administration Expenses


Neurocrine Biosciences reported $318.5M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Prothena USD 12.67M 5.02M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Repligen USD 76.54M 2.17M Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xoma USD 11M 2.54M Jun/2024